Access count of this item: 158

Files in This Item:
File Description SizeFormat 
38_285.pdf322.14 kBAdobe PDFView/Open
Title: マウス膀胱腫瘍(MBT-2)に対するTNFと癌化学療法剤との併用効果の検討
Other Titles: Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)
Authors: 池本, 慎一  KAKEN_name
飯盛, 宏記  KAKEN_name
西本, 憲一  KAKEN_name
早原, 信行  KAKEN_name
上水流, 雅人  KAKEN_name
和田, 誠次  KAKEN_name
前川, 正信  KAKEN_name
Author's alias: Ikemoto, Shinichi
Iimori, Hiroki
Nishimoto, Kenichi
Hayahara, Nobuyuki
Kamizuru, Masato
Wada, Seiji
Maekawa, Masanobu
Keywords: Murine bladder tumor
Tumor necrosis factor
Antitumor chemotherapeutic agent
Issue Date: Mar-1992
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 38
Issue: 3
Start page: 285
End page: 289
Abstract: マウス膀胱腫瘍(MBT-2)を用いてin vivoでTNFと各種癌化学療法剤(5-FU, CPM, CDDP, ADM)との併用効果を検討した.MBT-2にC3H/HeNマウスに移植し,移植後10日目よりTNF 3,000単位を10日間連続で腹腔内投与し各種癌化学療法剤は移植後10日目に1回だけ腹腔内投与を行った.腫瘍移植後20日目に効果を検討した.5-FU, CPM, ADMはTNFと併用することにより抗腫瘍効果が増強されたがCDDPでは増強効果を認めなかった
The antitumor activity of combination therapy of recombinant human tumor necrosis factor alpha (rHu-TNF alpha) and chemotherapeutic agents against murine bladder tumor (MBT-2) was studied. Tumors were intradermally transplanted into the hind leg of C3H-HeN mice and allowed to grow until they reached a diameter of 8 to 10 mm 10 days after transplantation. TNF (3,000 units) was given intraperitoneally from day 10 to day 19, and the chemotherapeutic agents, 5-FU (60 mg/kg), CPM (100 mg/kg), CDDP (10 mg/kg) and ADM (5 mg/kg), were applied once intraperitoneally on day 10. The antitumor effects were evaluated based on tumor volume on day 20. 5-FU, CPM and ADM enhanced the antitumor effect when combined with TNF, but CDDP did not. These findings suggest that combination therapy of TNF and certain antitumor chemotherapeutic agents is effective cancer treatment.
URI: http://hdl.handle.net/2433/117507
PubMed ID: 1523983
Appears in Collections:Vol.38 No.3

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.